Key facts
- It has raised $25.7M; the latest was Later Stage VC ($5.2M) in Oct 2024.
- Notable investors include Korea Investment Partners, Pureun Investment, GSA Private Equity, Industrial Bank of Korea, NAU IB Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for AMiPHARM
- ·The full record, as it builds
Funding rounds
No funding rounds for AMiPHARM are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AMiPHARM
Developer of a medication injection designed to be used for localized fat reduction. The company's injection specializes in polyene phosphatidylcholine, an endogenic substance extracted from soybeans at a purity that offers one-stop-all care for facial cosmetic surgery causing apoptosis and lipolysis in fat cells, enabling patients with a safe and stable injectable composition to improve unwanted submental fat.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2005
- Employees
- 8
- Website
- amipharm.com/
- Ownership
- Privately Held (backing)
AMiPHARM doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AMiPHARM shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AMiPHARM in its N-PORT filings yet. We sweep new filings monthly.